Santarus, Inc. : Santarus to Present at Jefferies 2012 Global Healthcare Conference
05/29/2012| 04:05am US/Eastern
Recommend:
Santarus,
Inc. (NASDAQ:SNTS) today announced that Gerald T. Proehl, president
and chief executive officer, will make a presentation at the Jefferies
2012 Global Healthcare Conference on Tuesday, June 5, 2012, at 2:30 p.m.
Eastern time (11:30 a.m. Pacific time) in New York City.
A webcast of the presentation will be available during the event at www.santarus.com
and will be archived and available on the website for 14 days.
About Santarus
Santarus, Inc. is a specialty biopharmaceutical company focused on
acquiring, developing and commercializing proprietary products that
address the needs of patients treated by physician specialists. The
company's current commercial efforts are focused on GLUMETZA®
(metformin hydrochloride extended release tablets) and CYCLOSET®
(bromocriptine mesylate) tablets, which are indicated as adjuncts to
diet and exercise to improve glycemic control in adults with type 2
diabetes, and on FENOGLIDE®
(fenofibrate) tablets, which is indicated as an adjunct to diet to
reduce high cholesterol.
Santarus has a diverse product development pipeline. A New Drug
Application for UCERIS™ (budesonide) tablets for induction of
remission of mild to moderate active ulcerative colitis is under review
by the U.S. Food and Drug Administration with a response expected in
October 2012. The pipeline also includes two late-stage investigational
drugs in Phase III clinical studies: recombinant human C1 inhibitor for
treatment of acute attacks of hereditary angioedema and rifamycin SV MMX®
for treatment of travelers' diarrhea. In addition, the company's
investigational monoclonal antibody, SAN-300, is being evaluated in a
Phase I clinical program. More information about Santarus is available
at www.santarus.com.
Santarus cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements. The inclusion of forward-looking statements should
not be regarded as a representation by Santarus that any of its plans
will be achieved. Actual results may differ materially from those
set forth in this release due to the risks and uncertainties inherent in
Santarus' business, including, without limitation: difficulties or
delays in development, testing, manufacturing and marketing of, and
obtaining and maintaining regulatory approvals for, Santarus' products;
and other risks detailed in Santarus' prior press releases as well as in
public periodic filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Santarus undertakes no obligation to revise or
update this news release to reflect events or circumstances after the
date hereof. This caution is made under the safe harbor
provisions of Section 21E of the Private Securities Litigation Reform
Act of 1995.
Santarus®, FENOGLIDE®
and UCERIS™ are trademarks of Santarus, Inc.
GLUMETZA® is a trademark of Biovail
Laboratories International S.r.l. licensed exclusively in the United
States to Depomed, Inc. CYCLOSET® is a
trademark of VeroScience LLC. MMX® is a
trademark of Cosmo Technologies Limited.
Santarus, Inc.
Martha L. Hough
VP Finance & Investor
Relations
(858) 314-5824
Debra P. Crawford
Chief
Financial Officer
(858) 314-5708
or
Investor Contact:
LHA
Jody
Cain (jcain@lhai.com)
Bruce
Voss (bvoss@lhai.com)
(310)
691-7100
@LHA_IR_PR
© Business Wire 2012
Recommend :
